Insight Molecular Diagnostics
- Country
- Ownership
- -
- Employees
- -
- Market Cap
- -
- Introduction
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
Clinical Trials
1
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
- Conditions
- Kidney Transplant RejectionCell-free DNA
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Insight Molecular Diagnostics
- Target Recruit Count
- 125
- Registration Number
- NCT07060716
- Locations
- 🇺🇸
University of Southern California Keck School of Medicine, Los Angeles, California, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇩🇪Institute of Immunology - Transplantation Immunology, Heidelberg, Baden-Wurttemberg, Germany
News
iMDx Enrolls First Patient in GraftAssureDx Transplant Rejection Monitoring Trial
iMDx has enrolled its first patient in the GraftAssureDx clinical trial, an observational study designed to validate a kitted transplant rejection monitoring test for kidney transplant recipients.
iMDx Digital PCR Platform Shows Equivalent Performance to NGS in Kidney Transplant Rejection Testing
iMDx's digital PCR-based GraftAssureIQ test demonstrated equivalent donor-derived cell-free DNA measurements compared to next-generation sequencing platforms in a head-to-head study of 96 kidney transplant recipients.